Vigamox 5 eye drops

Vigamox

How does this medication work? What will it do for me?

Moxifloxacin belongs to the class of medications known as fluoroquinolones. Fluoroquinolones are antibiotics that are used to treat infections caused by certain types of bacteria. Moxifloxacin ophthalmic solution is an antibiotic eye drop used to treat eye infections called bacterial conjunctivitis (pink eye) in people 12 months and older. It works by killing the bacteria that cause the infection.

This medication may be available under multiple brand names and/or in several different forms. Any specific brand name of this medication may not be available in all of the forms or approved for all of the conditions discussed here. As well, some forms of this medication may not be used for all of the conditions discussed here.

Your doctor may have suggested this medication for conditions other than those listed in these drug information articles. If you have not discussed this with your doctor or are not sure why you are being given this medication, speak to your doctor. Do not stop using this medication without consulting your doctor.

Do not give this medication to anyone else, even if they have the same symptoms as you do. It can be harmful for people to use this medication if their doctor has not prescribed it.

What form(s) does this medication come in?

Each mL of ophthalmic solution contains moxifloxacin base 5 mg. Nonmedicinal ingredients: boric acid, purified water, and sodium chloride. May also contain hydrochloric acid/sodium hydroxide to adjust pH.

How should I use this medication?

Moxifloxacin eye drops are usually used for a period of one week. Use one drop in the affected eye(s) 3 times a day while awake. You should space the doses evenly throughout the day.

Many things can affect the dose of medication that a person needs, such as body weight, other medical conditions, and other medications. If your doctor has recommended a dose different from the ones listed here, do not change the way that you are using the medication without consulting your doctor.

It is important to use this medication exactly as prescribed by your doctor. Use it for the full length of time your doctor has recommended, even if you have started to feel better.

To use the eye drops:

  1. Wash your hands before using the eye drops.
  2. Remove the cap and place it in a clean location. To avoid possible contamination, keep the tip of the container away from contact with any surface.
  3. Tilt your head back and look towards the ceiling.
  4. With your index finger, gently pull the lower eyelid down and away from the eye to form a pouch.
  5. Apply one drop into the pouch but do not allow the tip of the container to touch the eye or areas around the eye.
  6. Gently apply pressure to the inner corner of the eye (at the bridge of the nose) for about 30 seconds. (This is called nasolacrimal occlusion.) This prevents the medication from dripping down through the tear duct and entering the bloodstream, which could cause you to experience some side effects.
  7. Repeat with the other eye, if prescribed by your physician.
  8. Wash your hands again to remove any medication.

Safely discard any medication remaining in the dropper bottle after you have used the medication for the full length of time recommended by your doctor. Discard any remaining medication 28 days after opening the bottle.

Ask your doctor or pharmacist to show you the correct method of applying eye drops. It is very important to avoid touching the dropper tip to any surface, skin, or your eye. This contamination can result in a bacterial infection. Report any signs of an eye infection (e.g., redness, irritation, pain) to your doctor immediately.

If you miss a dose, instill it as soon as possible and continue with your regular schedule. If it is almost time for your next dose, skip the missed dose and continue with your regular dosing schedule. Do not administer a double dose to make up for a missed one. If you are not sure what to do after missing a dose, contact your doctor or pharmacist for advice.

Store this medication at room temperature and keep it out of the reach of children.

Do not dispose of medications in wastewater (e.g. down the sink or in the toilet) or in household garbage. Ask your pharmacist how to dispose of medications that are no longer needed or have expired.

Who should NOT take this medication?

Do not use this medication if you:

  • are allergic to moxifloxacin or any ingredients of the medication
  • are allergic to any fluoroquinolone antibiotics (e.g., ciprofloxacin, levofloxacin, gatifloxacin, ofloxacin, norfloxacin)

What side effects are possible with this medication?

Many medications can cause side effects. A side effect is an unwanted response to a medication when it is taken in normal doses. Side effects can be mild or severe, temporary or permanent.

The side effects listed below are not experienced by everyone who uses this medication. If you are concerned about side effects, discuss the risks and benefits of this medication with your doctor.

The following side effects have been reported by at least 1% of people using this medication. Many of these side effects can be managed, and some may go away on their own over time.

Contact your doctor if you experience these side effects and they are severe or bothersome. Your pharmacist may be able to advise you on managing side effects.

  • dry eye
  • eye irritation
  • eye itchiness
  • mild, temporary burning and stinging with application
  • nausea

Although most of the side effects listed below don’t happen very often, they could lead to serious problems if you do not seek medical attention.

Check with your doctor as soon as possible if any of the following side effects occur:

  • eye pain
  • other disorders of the area around the cornea
  • sensitivity to light
  • spots on the cornea
  • symptoms of a new eye infection (e.g., eye discharge, redness, itchiness or pain)
  • swelling of the cornea

Stop using the medication and seek immediate medical attention if any of the following occur:

  • signs of a serious allergic reaction, e.g.:
    • abdominal cramps
    • difficulty breathing
    • nausea and vomiting
    • swelling of the face and throat

Some people may experience side effects other than those listed. Check with your doctor if you notice any symptom that worries you while you are taking this medication.

Are there any other precautions or warnings for this medication?

Before you begin using a medication, be sure to inform your doctor of any medical conditions or allergies you may have, any medications you are taking, whether you are pregnant or breast-feeding, and any other significant facts about your health. These factors may affect how you should use this medication.

Allergic reactions: Moxifloxacin may cause a skin rash and other serious allergic reactions. If you notice a skin rash, skin blisters, skin itching, or hives, stop taking the medication and contact your doctor immediately.

Contact lenses: Avoid wearing contact lenses while you have signs and symptoms of bacterial conjunctivitis (eye infection).

New eye infections: Overgrowth of bacteria that are not affected by this medication may occur and cause a new eye infection. If you experience symptoms of a new eye infection (e.g., eye redness, discharge, pain or itching), contact your doctor.

Pregnancy: This medication should not be used during pregnancy unless the benefits outweigh the risks. If you become pregnant while taking this medication, contact your doctor immediately.

Breast-feeding: It is not known if moxifloxacin ophthalmic solution passes into breast milk. If you are a breast-feeding mother and are taking this medication, it may affect your baby. Talk to your doctor about whether you should continue breast-feeding.

Children: The safety and effectiveness of using this medication have not been established for children less than 12 months old.

What other drugs could interact with this medication?

Tell your doctor or prescriber about all prescription, over-the-counter (non-prescription), and herbal medications that you are taking. Also tell them about any supplements you take. Since caffeine, alcohol, the nicotine from cigarettes, or street drugs can affect the action of many medications, you should let your prescriber know if you use them. Depending on your specific circumstances, your doctor may want you to:

  • stop taking one of the medications,
  • change one of the medications to another,
  • change how you are taking one or both of the medications, or
  • leave everything as is.

An interaction between two medications does not always mean that you must stop taking one of them. Speak to your doctor about how any drug interactions are being managed or should be managed.

All material copyright MediResource Inc. 1996 – 2020. Terms and conditions of use. The contents herein are for informational purposes only. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Source: www.medbroadcast.com/drug/getdrug/Vigamox

Medical Editor: John P. Cunha, DO, FACOEP

Last reviewed on RxList 3/18/2019

Vigamox (moxifloxacin hydrochloride ophthalmic solution) is an antibiotic used to treat bacterial infections of the eyes. Common side effects of Vigamox include:

  • blurred vision,
  • watery eyes (tearing), and
  • eye (pain, dryness, redness, itching, burning, stinging, and irritation).

Serious side effects are not expected to occur during treatment with Vigamox. Tell your doctor if you have an unlikely but serious side effect of Vigamox such as swelling of the eye.

The dose of Vigamox: Instill one drop in the affected eye 3 times a day for 7 days. Do not use other eye drops or medications during treatment with Vigamox ophthalmic unless directed by your doctor. Other drugs may interact with Vigamox. Tell your doctor all prescription or over-the-counter medicines or supplements you use. Vigamox should be used only when prescribed during pregnancy. It is not known if this medication passes into breast milk. Consult your doctor before breastfeeding.

Our Vigamox (moxifloxacin hydrochloride ophthalmic solution) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Vigamox Side Effects

Generic Name: moxifloxacin ophthalmic

Medically reviewed by Drugs.com. Last updated on Nov 21, 2018.

  • Overview
  • Side Effects
  • Dosage
  • Professional
  • Pregnancy
  • More

Note: This document contains side effect information about moxifloxacin ophthalmic. Some of the dosage forms listed on this page may not apply to the brand name Vigamox.

For the Consumer

Applies to moxifloxacin ophthalmic: ophthalmic solution

Along with its needed effects, moxifloxacin ophthalmic (the active ingredient contained in Vigamox) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking moxifloxacin ophthalmic:

Incidence not known

  • Fainting or loss of consciousness
  • fast or irregular breathing
  • itching or skin rash
  • swelling of the eyes or eyelids
  • tightness in the chest
  • trouble with breathing

Some side effects of moxifloxacin ophthalmic may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

  • Burning, dry, or itching eyes
  • change in vision
  • decreased vision
  • dry eye
  • excessive tearing
  • eye discharge
  • itching of the eye
  • pain in the eye
  • red, sore eyes
  • tearing

Less common

  • Body aches or pain
  • congestion
  • cough or hoarseness
  • decreased hearing
  • dryness or soreness of the throat
  • fever or chills
  • general body discomfort
  • lower back or side pain
  • painful or difficult urination
  • rubbing or pulling of the ears (in children)
  • runny nose
  • sore throat
  • tender, swollen glands in the neck
  • trouble with swallowing
  • voice changes
  • vomiting and diarrhea (in infants)

For Healthcare Professionals

Applies to moxifloxacin ophthalmic: intraocular solution, ophthalmic solution

General

The most common side effects were eye irritation and eye pain.

Ocular

Common (1% to 10%): Conjunctivitis, decreased visual acuity, dry eye, keratitis, ocular discomfort, ocular hyperemia, ocular pain, ocular pruritus, subconjunctival hemorrhage, tearing, eye irritation, eye pain

Uncommon (0.1% to 1%): Punctuate keratitis, eye pruritus, conjunctival hemorrhage, eyelid edema

Rare (less than 0.1%): Corneal epithelium defect, corneal disorder, blepharitis, eye swelling, conjunctival edema, blurred vision, asthenopia, erythema of eyelid

Frequency not reported: Endophthalmitis, ulcerative keratitis, corneal erosion, corneal abrasion, intraocular pressure increased, corneal opacity, corneal infiltrates, corneal deposits, eye allergy, corneal edema, photophobia, lacrimation increased, eye discharge, foreign body sensation in eyes, corneal staining, eyelid disorder, abnormal sensation in eye

Respiratory

Common (1% to 10%): Increased cough, pharyngitis, rhinitis

Rare (less than 0.1%): Nasal discomfort, pharyngolaryngeal pain, sensation of foreign body (throat)

Frequency not reported: Dyspnea

Dermatologic

Common (1% to 10%): Rash

Frequency not reported: Erythema, pruritus, urticaria

Other

Common (1% to 10%): Otitis media, fever/pyrexia, infection

Nervous system

Uncommon (0.1% to 1%): Dysgeusia, headache

Rare (less than 0.1%): Paresthesia

Frequency not reported: Dizziness

Gastrointestinal

Rare (less than 0.1%): Vomiting

Frequency not reported: Nausea

Hematologic

Rare (less than 0.1%): Decreased hemoglobin

Hepatic

Rare (less than 0.1%): Increased ALT, increased GGT

Hypersensitivity

Serious and occasionally fatal hypersensitivity (anaphylactic) reactions (some after first dose) have been reported with systemic quinolones.

Frequency not reported: Hypersensitivity

Systemic quinolones:

-Frequency not reported: Hypersensitivity (anaphylactic) reactions

Cardiovascular

Frequency not reported: Palpitations

Musculoskeletal

Systemic fluoroquinolones:

-Frequency not reported: Tendon ruptures

Ruptures of the shoulder, hand, Achilles, or other tendons (requiring surgical repair or resulting in prolonged disability) have been reported with systemic fluoroquinolones. Risk of such ruptures may be increased in patients using concomitant corticosteroids, especially geriatric patients and in tendons under high stress (including the Achilles tendon).

1. “Product Information. Moxeza (moxifloxacin ophthalmic).” Alcon Laboratories Inc, Fort Worth, TX.

2. “Product Information. Vigamox (moxifloxacin ophthalmic).” Alcon Laboratories Inc, Fort Worth, TX.

3. Cerner Multum, Inc. “UK Summary of Product Characteristics.” O 0

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.

Medical Disclaimer

More about Vigamox (moxifloxacin ophthalmic)

  • During Pregnancy or Breastfeeding
  • Dosage Information
  • Compare Alternatives
  • Pricing & Coupons
  • En Español
  • 16 Reviews
  • Generic Availability
  • Drug class: ophthalmic anti-infectives
  • FDA Alerts (2)

Consumer resources

  • Vigamox
  • Vigamox (Advanced Reading)

Other brands: Moxeza

Professional resources

  • Vigamox eent (AHFS Monograph)
  • … +1 more

Related treatment guides

  • Ophthalmic Surgery
  • Conjunctivitis, Bacterial

GENERIC NAME: MOXIFLOXACIN – OPHTHALMIC (mox-ih-FLOX-uh-sin)

BRAND NAME(S): Vigamox

Medication Uses | How To Use | Side Effects | Precautions | Drug Interactions | Overdose | Notes | Missed Dose | Storage

USES: This medication is a quinolone antibiotic used for eye infections.

HOW TO USE: For best results, use exactly as directed for the full time prescribed. Stopping this medication too soon may result in a relapse of the infection.To apply eye drops, wash hands first. To avoid contamination, do not let the dropper tip touch any surface.Tilt your head back, gaze upward and pull down the lower eyelid to make a pouch. Place the dropper directly over eye and instill the prescribed number of drops. Look downward and gently close your eye for 1 to 2 minutes. Place one finger at the corner of the eye near the nose and apply gentle pressure. This will prevent the medication from draining away from the eye. Try not to blink and do not rub the eye. Do not rinse the dropper.If you are using other kinds of eye drops, wait at least five minutes before applying the other medications.Do not wear contact lenses while you are using this medicine. Sterilize contact lenses according to manufacturer’s directions and check with your doctor before using them.Inform you doctor if your condition does not improve in 7 days.

SIDE EFFECTS: Blurred vision, watery eyes, eye pain/dryness/redness/itchiness may occur. If any of these effects persist or worsen, inform your doctor.Remember that your doctor has prescribed this medication because he or she has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.Tell your doctor immediately if any of these unlikely but serious side effects occur: swelling of the eye.An allergic reaction to this drug is unlikely, but seek immediate medical attention if it occurs. Symptoms of an allergic reaction include: rash, itching/swelling (especially of the face/tongue/throat), dizziness, trouble breathing.This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.In the US -Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.In Canada – Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.

PRECAUTIONS: Before using this medication, tell your doctor or pharmacist if you are allergic to it; or to quinolone antibiotics (such as ciprofloxacin); or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.Before using this medication, tell your doctor or pharmacist your medical history, especially of: contact lens use.Your vision may be temporarily blurred or unstable after applying this drug. Do not drive, use machinery, or do any activity that requires clear vision until you are sure you can perform such activities safely.Use of this medication for prolonged or repeated periods may result in a secondary infection.This drug should be used only when clearly needed during pregnancy. Discuss the risks and benefits with your doctor.It is not known if this medication passes into breast milk. Consult your doctor before breast-feeding.

Vigamox Eye Medicine

VIGAMOX ANTIBACTERIAL EYE DROPS

(moxifloxacin hydrochloride ophthalmic solution 0.5%)

Vigamox is a topical ophthalmic antibiotic eye drop that is used for the treatment of bacterial conjunctivitis (a bacterial infection on the surface of the eye). It is manufactured by Alcon (Ft. Worth, TX) and is one of many antibacterial eye drops available in the U.S. Vigamox is available by doctor’s prescription only and is supplied in a 3 ML bottle.

Vigamox is similar to other fluoroquinolone eye drops such as Zymar (gatifloxacin), Ciloxan (ciprofloxacin) and Ocuflox (ofloxacin).

Possible Side Effects of Vigamox

Side effects after the use of Vigamox occur in 1-6% of the population. Systemic side effects can be decreased if the patient gently applies pressure to the tear drainage ducts on the lower eyelids for1 minute after instilling Vigamox eye drops. Possible side effects include the following:

Possible Mild effects of Vigamox:

  • Stinging/burning upon instillation of drops
  • Ocular irritation or redness
  • Increased tearing
  • Decrease in vision
  • Dry eyes

Possible Serious effects of Vigamox:

  • Fever
  • Increased coughing or difficulty breathing
  • Rash on skin
  • Swollen face and/or throat

Contraindications for Use of Vigamox

Vigmaox should not be used in any patients that have a known hypersensitivity or drug allergy to fluoroquinolones (a class of antibiotics). Caution should be used in female patients who are pregnant or who are nursing. Vigamox should not be used for viral or fungal infections of the eye.

Vigamox is in the FDA pregnancy category C (i.e. it is not known whether it will be harmful to an unborn baby). It is not known whether Vigamox passes into breast milk.

How to Use Vigamox

Standard dosing of Vigamox is 1 drop in the affected eye 3 times per day for 7 days. The dosing schedule may be altered depending on the severity of the bacterial infection. Vigamox is safe for use in patients over 1 year of age.

  • Contact lenses should not be worn while using Vigamox. Glasses should be used to correct vision until resolution of the condition.
  • If any serious side effects or signs of fluoroquinolone hypersensitivity are experienced (rash, itching, swelling of the face/throat, or difficulty breathing), the patient should stop using Vigamox immediately and contact his/her eye doctor.
  • Avoid contamination of medication by avoiding contact of the tip of the eye dropper with anything and by washing hands prior to use.
  • Use Vigamox for the entire time prescribed. Do not decrease or discontinue use of medication if symptoms subside.
  • Vigamox is a solution so it is not necessary to shake the bottle before instilling drops.

Vigamox Eye Drops

Generic Name: moxifloxacin ophthalmic (MOX i FLOX a sin)
Brand Names: Moxeza, Vigamox

Medically reviewed by Kaci Durbin, MD Last updated on Apr 30, 2019.

  • Overview
  • Side Effects
  • Dosage
  • Professional
  • Pregnancy
  • More

What is Vigamox?

Vigamox eye drops contain moxifloxacin, a fluoroquinolone antibiotic used to fight bacterial infections of the eye.

Vigamox will not treat a viral or fungal infection of the eye. This medicine is for use in treating only bacterial infections.

Important information

Do not use Vigamox if you have a viral or fungal infection in the eye. It is used to treat infections caused by bacteria only.

Before taking this medicine

You should not use Vigamox if you are allergic to moxifloxacin or other fluoroquinolones (ciprofloxacin, gemifloxacin, levofloxacin, ofloxacin, norfloxacin, and others).

Do not use Vigamox to treat a viral or fungal infection in the eye. This medicine is for use in treating only bacterial infections of the eye.

It is not known whether Vigamox will harm an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant.

It is not known whether Vigamox passes into breast milk or if it could affect the nursing baby. Tell your doctor if you are breast-feeding.

How should I use Vigamox?

Use Vigamox eye drops exactly as directed by your doctor. Follow all directions on your prescription label. Do not use this medicine in larger or smaller amounts or for longer than recommended.

If you wear contact lenses, remove them before using Vigamox eye drops. Ask your doctor if contact lenses can be reinserted after application of the medication.

Wash your hands before using the eye drops.

To apply the eye drops:

  • Tilt your head back slightly and pull down your lower eyelid to create a small pocket. Hold the dropper above the eye with the tip down. Look up and away from the dropper and squeeze out a drop.

  • Close your eyes for 2 or 3 minutes with your head tipped down, without blinking or squinting. Gently press your finger to the inside corner of the eye for about 1 minute, to keep the liquid from draining into your tear duct.

  • Use only the number of drops your doctor has prescribed. If you use more than one drop, wait about 5 minutes between drops.

  • Wait at least 10 minutes before using any other eye drops your doctor has prescribed.

Do not touch the tip of the eye dropper or place it directly on your eye. A contaminated dropper can infect your eye, which could lead to serious vision problems.

Vigamox is most often used for 7 days in a row. Use Vigamox for the full prescribed length of time. Your symptoms may improve before the infection is completely cleared.

Do not use the eye drops if the liquid has changed colors or has particles in it. Call your pharmacist for new medicine.

Store at cool room temperature, away from moisture and heat. Do not freeze. Keep the bottle tightly closed when not in use.

What happens if I miss a dose?

Use the missed dose as soon as you remember. Skip the missed dose if it is almost time for your next scheduled dose. Do not use extra medicine to make up the missed dose.

What happens if I overdose?

An overdose of Vigamox is not expected to be dangerous. Seek emergency medical attention or call the Poison Help line at 1-800-222-1222 if anyone has accidentally swallowed the medication.

What should I avoid while using Vigamox?

Avoid wearing contact lenses until you no longer have symptoms of the eye infection.

Vigamox may cause blurred vision. Be careful if you drive or do anything that requires you to be alert and able to see clearly.

Do not use other eye medications unless your doctor tells you to.

Vigamox side effects

Get emergency medical help if you have signs of an allergic reaction to Vigamox: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Call your doctor at once if you have:

  • severe burning, stinging, or irritation after using Vigamox eye drops; or

  • eye swelling, redness, severe discomfort, crusting or drainage (may be signs of infection).

Common Vigamox side effects may include:

  • dry eyes or watery eyes;

  • eye pain or discomfort;

  • blurred vision;

  • mild itching, redness, or other irritation; or

  • fever, cough, sore throat or runny nose.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What other drugs will affect Vigamox?

It is not likely that other drugs you take orally or inject will have an effect on moxifloxacin used in the eyes. But many drugs can interact with each other. Tell each of your healthcare providers about all medicines you use, including prescription and over-the-counter medicines, vitamins, and herbal products.

Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use Vigamox only for the indication prescribed.

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Copyright 1996-2020 Cerner Multum, Inc. Version: 3.01.

Medical Disclaimer

  • Side Effects
  • During Pregnancy or Breastfeeding
  • Dosage Information
  • Compare Alternatives
  • Pricing & Coupons
  • En Español
  • 16 Reviews
  • Generic Availability
  • Drug class: ophthalmic anti-infectives
  • FDA Alerts (2)
  • Vigamox
  • Vigamox (Advanced Reading)

Other brands: Moxeza

  • Vigamox eent (AHFS Monograph)
  • … +1 more
  • Ophthalmic Surgery
  • Conjunctivitis, Bacterial

Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. When you are taking this medicine, it is especially important that your healthcare professional know if you are taking any of the medicines listed below. The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive.

Using this medicine with any of the following medicines is not recommended. Your doctor may decide not to treat you with this medication or change some of the other medicines you take.

  • Cisapride
  • Mesoridazine
  • Pimozide
  • Piperaquine
  • Saquinavir
  • Sparfloxacin
  • Terfenadine
  • Thioridazine
  • Ziprasidone

Using this medicine with any of the following medicines is usually not recommended, but may be required in some cases. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.

  • Acarbose
  • Acetohexamide
  • Alfuzosin
  • Alogliptin
  • Amiodarone
  • Amitriptyline
  • Apomorphine
  • Arsenic Trioxide
  • Asenapine
  • Astemizole
  • Atazanavir
  • Azithromycin
  • Bedaquiline
  • Benfluorex
  • Canagliflozin
  • Chloroquine
  • Chlorpromazine
  • Chlorpropamide
  • Ciprofloxacin
  • Citalopram
  • Clarithromycin
  • Clomipramine
  • Clozapine
  • Crizotinib
  • Cyclobenzaprine
  • Dabrafenib
  • Dapagliflozin
  • Dasatinib
  • Delamanid
  • Desipramine
  • Disopyramide
  • Dofetilide
  • Dolasetron
  • Domperidone
  • Donepezil
  • Doxepin
  • Droperidol
  • Ebastine
  • Eribulin
  • Ertugliflozin
  • Erythromycin
  • Escitalopram
  • Exenatide
  • Famotidine
  • Felbamate
  • Flecainide
  • Fluconazole
  • Fluoxetine
  • Foscarnet
  • Fosphenytoin
  • Galantamine
  • Gatifloxacin
  • Gemifloxacin
  • Gliclazide
  • Glimepiride
  • Glipizide
  • Gliquidone
  • Glyburide
  • Granisetron
  • Halofantrine
  • Haloperidol
  • Hydroquinidine
  • Ibutilide
  • Iloperidone
  • Imipramine
  • Insulin
  • Insulin Aspart, Recombinant
  • Insulin Bovine
  • Insulin Degludec
  • Insulin Detemir
  • Insulin Glargine, Recombinant
  • Insulin Glulisine
  • Insulin Lispro, Recombinant
  • Itraconazole
  • Ivabradine
  • Ketoconazole
  • Lapatinib
  • Lenvatinib
  • Levofloxacin
  • Linagliptin
  • Liraglutide
  • Lumefantrine
  • Mefloquine
  • Metformin
  • Methadone
  • Mifepristone
  • Miglitol
  • Mizolastine
  • Nateglinide
  • Nelfinavir
  • Nilotinib
  • Norfloxacin
  • Octreotide
  • Ofloxacin
  • Olanzapine
  • Ondansetron
  • Paliperidone
  • Panobinostat
  • Paroxetine
  • Pasireotide
  • Pazopanib
  • Pentamidine
  • Perphenazine
  • Pioglitazone
  • Pipamperone
  • Posaconazole
  • Pramlintide
  • Probucol
  • Procainamide
  • Prochlorperazine
  • Promethazine
  • Propafenone
  • Protriptyline
  • Quetiapine
  • Quinidine
  • Quinine
  • Ranolazine
  • Rasagiline
  • Repaglinide
  • Rilpivirine
  • Risperidone
  • Ritonavir
  • Rosiglitazone
  • Saxagliptin
  • Sertindole
  • Sevoflurane
  • Sitagliptin
  • Sodium Phosphate
  • Sodium Phosphate, Dibasic
  • Sodium Phosphate, Monobasic
  • Solifenacin
  • Sorafenib
  • Sotalol
  • Sunitinib
  • Tacrolimus
  • Tamoxifen
  • Telaprevir
  • Telavancin
  • Telithromycin
  • Tetrabenazine
  • Tizanidine
  • Tolazamide
  • Tolbutamide
  • Tolterodine
  • Toremifene
  • Trazodone
  • Trimipramine
  • Vandetanib
  • Vardenafil
  • Venlafaxine
  • Vildagliptin
  • Vinflunine
  • Voriconazole
  • Vorinostat
  • Warfarin

Using this medicine with any of the following medicines may cause an increased risk of certain side effects, but using both drugs may be the best treatment for you. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.

  • Rifampin

PMC

  • Abshire R, Cockrum P, et al. Topical antibacterial therapy for mycobacterial keratitis: potential for surgical prophylaxis and treatment. Clin Ther. 2004;26:191–6.
  • Alexandrakis G, Alfonso EC, et al. Shifting trends in bacterial keratitis in south Florida and emerging resistance to fluoroquinolones. Ophthalmology. 2000;107:1497–502.
  • Alfonso E, Crider J. Ophthalmic infections and their anti-infective challenges. Surv Ophthalmol. 2005;50(Suppl 1):S1–6.
  • Allen GP, Kaatz GW, et al. In vitro activities of mutant prevention concentration-targeted concentrations of fluoroquinolones against Staphylococcus aureus in a pharmacodynamic model. Int J Antimicrob Agents. 2004;24:150–60.
  • Appelbaum PC, Hunter PA. The fluoroquinolone antibacterials: past, present and future perspectives. Int J Antimicrob Agents. 2000;16:5–15.
  • Ball P, Fernald A, et al. Therapeutic advances of new fluoroquinolones. Expert Opin Investig Drugs. 1998;7:761–83.
  • Ball P, Stahlmann R, et al. Safety profile of oral and intravenous moxifloxacin: cumulative data from clinical trials and postmarketing studies. Clin Ther. 2004;26:940–50.
  • Blondeau JM. Expanded activity and utility of the new fluoroquinolones: a review. Clin Ther. 1999;21:3–40. discussion 1–2.
  • Blondeau JM. A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new respiratory quinolones. J Antimicrob Chemother. 1999;43(Suppl B):1–11.
  • Burka JM, Bower KS, et al. The effect of fourth-generation fluoroquinolones gatifloxacin and moxifloxacin on epithelial healing following photorefractive keratectomy. Am J Ophthalmol. 2005;140:83–7.
  • Burka JM, Bower KS, et al. The effect of moxifloxacin and gatifloxacin on long-term visual outcomes following photorefractive keratectomy. J Refract Surg. 2007;23:414–7.
  • Caeiro JP, Iannini PB. Moxifloxacin (Avelox): a novel fluoroquinolone with a broad spectrum of activity. Expert Rev Anti Infect Ther. 2003;1:363–70.
  • Cekic O, Batman C, et al. Penetration of ofloxacin and ciprofloxacin in aqueous humor after topical administration. Ophthalmic Surg Lasers. 1999a;30:465–8.
  • Cekic O, Batman C, et al. Human aqueous and vitreous humour levels of ciprofloxacin following oral and topical administration. Eye. 1999b;13:555–8.
  • Chang Lin JE, Welty D. Ocular pharmacokinetics of moxifloxacin after topical treatment of animals and humans. Surv Ophthalmol. 2006;51:530. author reply 530–1.
  • Chaudhry NA, Flynn HW, Jr, et al. Emerging ciprofloxacin-resistant Pseudomonas aeruginosa. Am J Ophthalmol. 1999;128:509–10.
  • Costello P, Bakri SJ, et al. Vitreous penetration of topical moxifloxacin and gatifloxacin in humans. Retina. 2006;26:191–5.
  • Dalhoff A, Schmitz FJ. In vitro antibacterial activity and pharmacodynamics of new quinolones. Eur J Clin Microbiol Infect Dis. 2003;22:203–21.
  • Deramo VA, Lai JC, et al. Acute endophthalmitis in eyes treated prophylactically with gatifloxacin and moxifloxacin. Am J Ophthalmol. 2006;142:721–5.
  • Domagala JM. Structure-activity and structure-side-effect relationships for the quinolone antibacterials. J Antimicrob Chemother. 1994;33:685–706.
  • Donaldson KE, Marangon FB, et al. The effect of moxifloxacin on the normal human cornea. Curr Med Res Opin. 2006;22:2073–80.
  • Donnenfeld E, Perry HD, et al. A comparison of the fourth-generation fluoroquinolones gatifloxacin 0.3% and moxifloxacin 0.5% in terms of ocular tolerability. Curr Med Res Opin. 2004;20:1753–8.
  • Donnenfeld ED, Kim T, et al. ASCRS White Paper: Management of infectious keratitis following laser in situ keratomileusis. J Cataract Refract Surg. 2005;31:2008–11.
  • Drlica K, Malik M. Fluoroquinolones: action and resistance. Curr Top Med Chem. 2003;3:249–82.
  • Durrie DS, Trattler W. A comparison of therapeutic regimens containing moxifloxacin 0.5% ophthalmic solution and gatifloxacin 0.3% ophthalmic solution for surgical prophylaxis in patients undergoing LASIK or LASEK. J Ocul Pharmacol Ther. 2005;21:236–41.
  • Endophthalmitis Vitrectomy Study Group. Results of the Endophthalmitis Vitrectomy Study. A randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis. Endophthalmitis Vitrectomy Study Group. Arch Ophthalmol. 1995;113:1479–96.
  • Freitas D, Alvarenga L, et al. An outbreak of Mycobacterium chelonae infection after LASIK. Ophthalmology. 2003;110:276–85.
  • Fuller JJ, Lott MN, et al. Vitreal penetration of oral and topical moxifloxacin in humans. Am J Ophthalmol. 2007;143:338–40.
  • Garcia-Saenz MC, Arias-Puente A, et al. Human aqueous humor levels of oral ciprofloxacin, levofloxacin, and moxifloxacin. J Cataract Refract Surg. 2001;27:1969–74.
  • Goldstein MH, Kowalski RP, et al. Emerging fluoroquinolone resistance in bacterial keratitis:a 5-year review. Ophthalmology. 1999;106:1313–8.
  • Griggs DJ, Marona H, et al. Selection of moxifloxacin-resistant Staphylococcus aureus compared with five other fluoroquinolones. J Antimicrob Chemother. 2003;51:1403–7.
  • Gupta V, Gupta A, et al. Presumed tubercular serpiginouslike choroiditis: clinical presentations and management. Ophthalmology. 2003;110:1744–9.
  • Haimann MH, Weiss H, et al. The Endophthalmitis Vitrectomy Study. Arch Ophthalmol. 1996;114:1025. author reply 1026–7.
  • Han DP, Wisniewski SR, et al. Spectrum and susceptibilities of microbiologic isolates in the Endophthalmitis Vitrectomy Study. Am J Ophthalmol. 1996;122:1–17.
  • Hariprasad SM, Blinder KJ, et al. Penetration pharmacokinetics of topically administered 0.5% moxifloxacin ophthalmic solution in human aqueous and vitreous. Arch Ophthalmol. 2005;123:39–44.
  • Hariprasad SM, Shah GK, et al. Determination of aqueous and vitreous concentration of moxifloxacin 0.5% after delivery via a dissolvable corneal collagen shield device. J Cataract Refract Surg. 2005;31:2142–6.
  • Hariprasad SM, Shah GK, et al. Vitreous and aqueous penetration of orally administered moxifloxacin in humans. Arch Ophthalmol. 2006;124:178–82.
  • Harper T, Miller D, et al. In vitro efficacy and pharmacodynamic indices for antibiotics against coagulase-negative Staphylococcus endophthalmitis isolates. Ophthalmology. 2007;114:871–5.
  • Hermsen ED, Hovde LB, et al. Mutant prevention concentrations of ABT-492, levofloxacin, moxifloxacin, and gatifloxacin against three common respiratory pathogens. Antimicrob Agents Chemother. 2005;49:1633–5.
  • Hofling-Lima AL, de Freitas D, et al. In vitro activity of fluoroquinolones against Mycobacterium abscessus and Mycobacterium chelonae causing infectious keratitis after LASIK in Brazil. Cornea. 2005;24:730–4.
  • Hooper DC. Emerging mechanisms of fluoroquinolone resistance. Emerg Infect Dis. 2001a;7:337–41.
  • Hooper DC. Mechanisms of action of antimicrobials: focus on fluoroquinolones. Clin Infect Dis. 2001b;32(Suppl 1):S9–S15.
  • Hwang DG. Fluoroquinolone resistance in ophthalmology and the potential role for newer ophthalmic fluoroquinolones. Surv Ophthalmol. 2004;49(Suppl 2):S79–83.
  • Ince D, Zhang X, et al. Activity of and resistance to moxifloxacin in Staphylococcus aureus. Antimicrob Agents Chemother. 2003;47:1410–5.
  • Jacoby GA. Mechanisms of resistance to quinolones. Clin Infect Dis. 2005;41(Suppl 2):S120–6.
  • John T, Velotta E. Nontuberculous (atypical) mycobacterial keratitis after LASIK: current status and clinical implications. Cornea. 2005;24:245–55.
  • Kampougeris G, Antoniadou A, et al. Penetration of moxifloxacin into the human aqueous humour after oral administration. Br J Ophthalmol. 2005;89:628–31.
  • Karp CL, Tuli SS, et al. Infectious keratitis after LASIK. Ophthalmology. 2003;110:503–10.
  • Katz HR, Masket S, et al. Absorption of topical moxifloxacin ophthalmic solution into human aqueous humor. Cornea. 2005;24:955–8.
  • Kaufman SC, Rusinek C, et al. Comparison of the biocompatibility of gatifloxacin 0.3% and moxifloxacin 0.5% Cornea. 2006;25(9 Suppl 2):S31–4.
  • Keating GM, Scott LJ. Moxifloxacin: a review of its use in the management of bacterial infections. Drugs. 2004;64:2347–77.
  • Kim DH, Stark WJ, et al. Ocular penetration of moxifloxacin 0.5% and gatifloxacin 0.3% ophthalmic solutions into the aqueous humor following topical administration prior to routine cataract surgery. Curr Med Res Opin. 2005a;21:93–4.
  • Kim DH, Stark WJ, et al. Aqueous penetration and biological activity of moxifloxacin 0.5% ophthalmic solution and gatifloxacin 0.3% solution in cataract surgery patients. Ophthalmology. 2005b;112:1992–6.
  • Kleinmann G, Larson S, et al. Intraocular concentrations of gatifloxacin and moxifloxacin in the anterior chamber via diffusion through the cornea using collagen shields. Cornea. 2006;25:209–13.
  • Koch HR, Kulus SC, et al. Corneal penetration of fluoroquinolones: aqueous humor concentrations after topical application of levofloxacin 0.5% and ofloxacin 0.3% eyedrops. J Cataract Refract Surg. 2005;31:1377–85.
  • Kotlus BS, Wymbs RA, et al. In vitro activity of fluoroquinolones, vancomycin, and gentamicin against methicillin-resistant Staphylococcus aureus ocular isolates. Am J Ophthalmol. 2006;142:726–9.
  • Kovoor TA, Kim AS, et al. Evaluation of the corneal effects of topical ophthalmic fluoroquinolones using in vivo confocal microscopy. Eye Contact Lens. 2004;30:90–4.
  • Kowalski RP, Dhaliwal DK, et al. Gatifloxacin and moxifloxacin:an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates. Am J Ophthalmol. 2003;136:500–5.
  • Kowalski RP, Yates KA, et al. An ophthalmologist’s guide to understanding antibiotic susceptibility and minimum inhibitory concentration data. Ophthalmology. 2005;112:1987.
  • Krasemann C, Meyer J, et al. Evaluation of the clinical microbiology profile of moxifloxacin. Clin Infect Dis. 2001;32(Suppl 1):S51–63.
  • Lee SB, Oliver KM, et al. Fourth-generation fluoroquinolones in the treatment of mycobacterial infectious keratitis after laser-assisted in situ keratomileusis surgery. Can J Ophthalmol. 2005;40:750–3.
  • Ly LT, Cavanagh HD, et al. Confocal assessment of the effects of fourth-generation fluoroquinolones on the cornea. Eye Contact Lens. 2006;32:161–5.
  • Mah FS. Fourth-generation fluoroquinolones: new topical agents in the war on ocular bacterial infections. Curr Opin Ophthalmol. 2004;15:316–20.
  • Mallari PL, McCarty DJ, et al. Increased incidence of corneal perforation after topical fluoroquinolone treatment for microbial keratitis. Am J Ophthalmol. 2001;131:131–3.
  • Marangon FB, Miller D, et al. Ciprofloxacin and levofloxacin resistance among methicillin-sensitive Staphylococcus aureus isolates from keratitis and conjunctivitis. Am J Ophthalmol. 2004;137:453–8.
  • Mather R, Karenchak LM, et al. Fourth generation fluoroquinolones: new weapons in the arsenal of ophthalmic antibiotics. Am J Ophthalmol. 2002;133:463–6.
  • Mather R, Stewart JM, et al. The effect of cataract surgery on ocular levels of topical moxifloxacin. Am J Ophthalmol. 2004;138:554–9.
  • Matieli LC, De Freitas D, et al. Mycobacterium abscessus endophthalmitis: treatment dilemma and review of the literature. Retina. 2006;26:826–9.
  • Matsumoto S, Way W, et al. Comparative toxicity of fluoroquinolone antibiotics on corneal cells in vitro. Cornea. 2006;25(9 Suppl 2):S1–7.
  • McCulley JP, Caudle D, et al. Fourth-generation fluoroquinolone penetration into the aqueous humor in humans. Ophthalmology. 2006;113:955–9.
  • McDermott M, Wheater M. In vitro comparison of the effects of clinically available ophthalmic solutions of gatifloxacin 0.3% and moxifloxacin 0.5% on human corneal and conjunctival epithelial cell adhesion and migration and on collagen type IV protein expression. Cornea. 2006;25(9 Suppl 2):S25–S30.
  • McGee DH, Holt WF, et al. Safety of moxifloxacin as shown in animal and in vitro studies. Surv Ophthalmol. 2005;50(Suppl 1):S46–54.
  • Metzler K, Hansen GM, et al. Comparison of minimal inhibitory and mutant prevention drug concentrations of 4 fluoroquinolones against clinical isolates of methicillin-susceptible and -resistant Staphylococcus aureus. Int J Antimicrob Agents. 2004;24:161–7.
  • Miller D, Alfonso EC. Comparative in vitro activity of levofloxacin, ofloxacin, and ciprofloxacin against ocular streptococcal isolates. Cornea. 2004;23:289–93.
  • Miller D, Flynn PM, et al. In vitro fluoroquinolone resistance in staphylococcal endophthalmitis isolates. Arch Ophthalmol. 2006;124:479–83.
  • Miller JJ, Scott IU, et al. Acute-onset endophthalmitis after cataract surgery (2000–2004): incidence, clinical settings, and visual acuity outcomes after treatment. Am J Ophthalmol. 2005;139:983–7.
  • Mino de Kaspar H, Koss MJ, et al. Antibiotic susceptibility of preoperative normal conjunctival bacteria. Am J Ophthalmol. 2005;139:730–3.
  • Moshirfar M, Meyer JJ, et al. Fourth-generation fluoroquinolone-resistant mycobacterial keratitis after laser in situ keratomileusis. J Cataract Refract Surg. 2007;33:1978–81.
  • Moshirfar M, Mirzaian G, et al. Fourth-generation fluoroquinolone-resistant bacterial keratitis after refractive surgery. J Cataract Refract Surg. 2006;32:515–8.
  • Munir WM, Rosenfeld SI, et al. Clinical response of contact lens-associated fungal keratitis to topical fluoroquinolone therapy. Cornea. 2007;26:621–4.
  • Nielsen JS, Blatt S, et al. Clinicopathologic case report: scleral buckle associated nontuberculous mycobacterial scleritis. Semin Ophthalmol. 2004;19(3–4):101–4.
  • O’Brien TP. Evidence-based review of moxifloxacin. Int Ophthalmol Clin. 2006;46:61–72.
  • Oliphant CM, Green GM. Quinolones: a comprehensive review. Am Fam Physician. 2002;65:455–64.
  • Oliveira AD, D’Azevedo PA, et al. In vitro activity of fluoroquinolones against ocular bacterial isolates in Sao Paulo, Brazil. Cornea. 2007;26:194–8.
  • Ong-Tone L. Aqueous humor penetration of gatifloxacin and moxifloxacin eyedrops given by different methods before cataract surgery. J Cataract Refract Surg. 2007;33:59–62.
  • Ozdek SC, Miller D, et al. In vitro antifungal activity of the fourth generation fluoroquinolones against Candida isolates from human ocular infections. Ocul Immunol Inflamm. 2006;14:347–51.
  • Peterson LR. Quinolone molecular structure-activity relationships: what we have learned about improving antimicrobial activity. Clin Infect Dis. 2001;33(Suppl 3):S180–6.
  • Pong A, Thomson KS, et al. Activity of moxifloxacin against pathogens with decreased susceptibility to ciprofloxacin. J Antimicrob Chemother. 1999;44:621–7.
  • Robertson SM, Curtis MA, et al. Ocular pharmacokinetics of moxifloxacin after topical treatment of animals and humans. Surv Ophthalmol. 2005;50(Suppl 1):S32–45.
  • Robicsek A, Jacoby GA, et al. The worldwide emergence of plasmid-mediated quinolone resistance. Lancet Infect Dis. 2006;6:629–40.
  • Robicsek A, Strahilevitz J, et al. Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase. Nat Med. 2006;12:83–8.
  • Saravolatz LD, Leggett J. Gatifloxacin, gemifloxacin, and moxifloxacin:the role of 3 newer fluoroquinolones. Clin Infect Dis. 2003;37:1210–5.
  • Schlech BA, Alfonso E. Overview of the potency of moxifloxacin ophthalmic solution 0.5% (VIGAMOX) Surv Ophthalmol. 2005;50(Suppl 1):S7–15.
  • Sharma SKDY, et al. Trends in antibiotic resistance of corneal pathogens: Part I. An Analysis of commonly used antibiotics. Indian J Ophthalmol. 1999;47:95–100.
  • Smith A, Pennefather PM, et al. Fluoroquinolones: place in ocular therapy. Drugs. 2001;61:747–61.
  • Smith HJ, Walters M, et al. Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates. Antimicrob Agents Chemother. 2004;48:3954–8.
  • Solomon R, Donnenfeld ED, et al. Bilateral methicillin-resistant staphylococcus aureus keratitis in a medical resident following an uneventful bilateral photorefractive keratectomy. Eye Contact Lens. 2003;29:187–9.
  • Solomon R, Donnenfeld ED, et al. Methicillin-resistant Staphylococcus aureus infectious keratitis following refractive surgery. Am J Ophthalmol. 2007;143:629–34.
  • Solomon R, Donnenfeld ED, et al. Penetration of topically applied gatifloxacin 0.3%, moxifloxacin 0.5%, and ciprofloxacin 0.3% into the aqueous humor. Ophthalmology. 2005;112:466–9.
  • Spencer TS, Teske MP, et al. Postcataract endophthalmitis caused by Mycobacterium goodii. J Cataract Refract Surg. 2005;31:1252–3.
  • Stern ME, Gao J, et al. Effects of fourth-generation fluoroquinolones on the ocular surface, epithelium, and wound healing. Cornea. 2006;25(9 Suppl 2):S12–S24.
  • Stroman DW, Dajcs JJ, et al. In vitro and in vivo potency of moxifloxacin and moxifloxacin ophthalmic solution 0.5%, a new topical fluoroquinolone. Surv Ophthalmol. 2005;50(Suppl 1):S16–31.
  • Takei M, Fukuda H, et al. Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition. Antimicrob Agents Chemother. 2001;45:3544–7.
  • Van Bambeke F, Michot JM, et al. Quinolones in 2005: an update. Clin Microbiol Infect. 2005;11:256–80.
  • Vedantham V, Lalitha P, et al. Vitreous and aqueous penetration of orally administered moxifloxacin in humans. Eye. 2006;20:1273–8.
  • Vigamox. 2004. . Fort Worth, TX, Alcon Laboratories.
  • Walter K, Tyler ME. Severe corneal toxicity after topical fluoroquinolone therapy: report of two cases. Cornea. 2006;25:855–7.
  • Walter S, Kuchenbecker J, et al. Concentration of moxifloxacin in serum and human aqueous humor following a single 400 mg oral dose. J Cataract Refract Surg. 2007;33:553–5.
  • Wilhelmus KR. Evaluation and prediction of fluoroquinolone pharma-codynamics in bacterial keratitis. J Ocul Pharmacol Ther. 2003;19:493–9.
  • Wilhelmus KR. Nontuberculous mycobacterial endophthalmitis. Arch Ophthalmol. 2003;121:1663.
  • Wilhelmus KR, Abshire RL, et al. Influence of fluoroquinolone susceptibility on the therapeutic response of fluoroquinolone-treated bacterial keratitis. Arch Ophthalmol. 2003;121:1229–33.
  • Winthrop KL, Steinberg EB, et al. Epidemic and sporadic cases of nontuberculous mycobacterial keratitis associated with laser in situ keratomileusis. Am J Ophthalmol. 2003;135:223–4.
  • Wise R. Maximizing efficacy and reducing the emergence of resistance. J Antimicrob Chemother. 2003;51(Suppl 1):7–42.
  • Woodward M, Randleman JB. Bilateral methicillin-resistant Staphylococcus aureus keratitis after photorefractive keratectomy. J Cataract Refract Surg. 2007;33:316–9.
  • Zhanel GG, Ennis K, et al. A critical review of the fluoroquinolones: focus on respiratory infections. Drugs. 2002;62:13–59.
  • Zhanel GG, Fontaine S, et al. A review of new fluoroquinolones: focus on their use in respiratory tract infections. Treat Respir Med. 2006;5:437–65.
  • Zhanel GG, Noreddin AM. Pharmacokinetics and pharmacodynamics of the new fluoroquinolones: focus on respiratory infections. Curr Opin Pharmacol. 2001;1:459–63.

About the author

Leave a Reply

Your email address will not be published. Required fields are marked *